Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2 Multicenter Trial of ICOS Agonist Monoclonal Antibody (mAb) Vopratelimab (JTX -2011) and a CTLA-4 Inhibitor in PD-1/PD-L1 Inhibitor Experienced Adult Subjects With Non-small Cell Lung Cancer or Urothelial Cancer

NCT03989362 is registered in ClinicalTrials.gov with Jounce Therapeutics, Inc. as lead sponsor.

NCT NCT03989362
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03989362 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2 Multicenter Trial of ICOS Agonist Monoclonal Antibody (mAb) Vopratelimab (JTX -2011) and a CTLA-4 Inhibitor in PD-1/PD-L1 Inhibitor Experienced Adult Subjects With Non-small Cell Lung Cancer or Urothelial Cancer
Lead sponsor
Jounce Therapeutics, Inc.
Phase
Phase 2
Overall status
Completed
Start date
June 6, 2019
Completion date
March 15, 2022
Enrollment
61 (actual)
Sites
21

Conditions

As the registry lists them; a condition with its own page is linked.

cancer